Lumos Pharma
Biotechnology, 4200 Marathon BLVD Ste 200, Austin, Texas, 78756, United States, 11-50 Employees
Phone Number: 15*********
Who is LUMOS PHARMA
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, ...
Read More
-
Headquarters: 4200 Marathon BLVD Ste 200, Austin, Texas, 78756, United States
-
Date Founded: 1999
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
David Gonzales
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 446110 |
Show More
Does something look wrong? Fix it. | View contact records from LUMOS PHARMA
Lumos Pharma Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Lumos Pharma
Answer: Lumos Pharma's headquarters are located at 4200 Marathon BLVD Ste 200, Austin, Texas, 78756, United States
Answer: Lumos Pharma's phone number is 15*********
Answer: Lumos Pharma's official website is https://lumos-pharma.com
Answer: Lumos Pharma's revenue is $1 Million to $5 Million
Answer: Lumos Pharma's SIC: 2834
Answer: Lumos Pharma's NAICS: 446110
Answer: Lumos Pharma has 11-50 employees
Answer: Lumos Pharma is in Biotechnology
Answer: Lumos Pharma contact info: Phone number: 15********* Website: https://lumos-pharma.com
Answer: Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients. Lumos Pharmas clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment. As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month